Drug-Related STI Prevention: Study Reveals Key Gaps

Substance Use and STI Transmission: The Crisis Behind the Numbers

Research across multiple developed nations reveals a clear crisis: substance use is systematically driving sexually transmitted infection rates upward, yet prevention strategies remain inadequate. The evidence demonstrates that drug consumption fundamentally compromises sexual health decision-making, creating infection pathways that current approaches fail to address.

Analysis of 55,690 young adults aged 18-25 in the United States provides stark evidence of this connection. Those using illicit drugs face 3.10 times higher odds (95% CI: 2.77-3.47) of contracting sexually transmitted infections compared to non-users. This represents one of the strongest statistical associations documented in public health research, yet prevention strategies targeting this relationship remain underdeveloped.

The data shows that some groups are more at risk than others. Men are more than twice as likely as women to get STIs. Young adults aged 22–25 have a higher risk than those aged 18–21. The greatest concern lies with individuals who have a history of delinquency, as they are more than twice as likely to become infected. These patterns highlight how risky behaviours are often interconnected, underscoring the need for prevention strategies that address these issues holistically.

How Substance Use Compromises Sexual Health Protection

Research from Dutch STI clinics involving 11,714 young people shows how drug use undermines infection prevention. Alcohol was used during sex by 45.3% of attendees, with men more likely than women to report this (49.5% vs 43.2%, p<0.001). Drug use during sex was reported by 22.0% of attendees, again more common among men (30.7%) than women (17.6%, p<0.001).

The most commonly reported substances were cannabis (17.9%), ecstasy/MDMA (6.9%), and cocaine (4.7%). Critically, the research demonstrates that drug use during sex correlates directly with risky sexual behaviours: inconsistent condom use (aOR: 2.5, 95% CI 1.9 to 3.2) and having four or more sexual partners within six months (aOR: 3.2, 95% CI 2.8 to 3.6).

Dr Andrady, sexual health consultant for Betsi Cadwaladr University Health Board, explains the clinical reality: “We have definitely seen a rise in people coming into the clinic after having sex whilst under the influence of drugs and alcohol, and they regret what they have done. People forget about protection when they are under the influence of drugs and alcohol.”

Geographic Evidence: The Spreading Crisis

Australian national data demonstrates how this crisis manifests geographically. Analysis from UNSW’s Kirby Institute shows syphilis notification rates grew in 277 out of 311 measurable locations over seven years. Chlamydia rates increased in 171 of 331 comparable places, whilst gonorrhoea rates increased in more than 90% of locations nationwide.

The pattern affects both urban and regional areas. Adelaide’s city region recorded the largest national increase in chlamydia rates, followed by Victoria’s affluent Stonnington West region (South Yarra, Toorak, Armadale, Windsor). Queensland recorded 1,467 syphilis cases in the most recent year, whilst Tasmania witnessed gonorrhoea cases quadrupling between 2016 and 2023.

Specific regional surges illustrate the crisis trajectory. The Gold Coast’s Southport region saw syphilis cases increase from 25 per 100,000 people in 2016 to 127 in 2023—a five-fold increase in seven years. Victoria’s Yarra region, including Richmond and Collingwood, recorded the largest gonorrhoea increase for urban areas.

Spanish research examining 563 participants reveals the most severe intersection of drug use and sexual activity. Among this population, 14.7% engaged in “slamsex”—intravenous drug injection during sexual activity—within a single year. This is the highest-risk behaviour, and nearly 18% were diagnosed with an STI within six months.

The research found that 63.7% used methamphetamines as their primary drug in chemsex practices. Even among the 21% receiving pre-exposure prophylaxis (PrEP) treatment, infection rates remained high, with statistically significant associations for gonorrhoea (p<0.001), chlamydia (p<0.001), genital herpes (p=0.020), and syphilis (p<0.001).

Dr Ezard describes the severe medical consequences: “People have come forward with issues around injuries that they’ve sustained while they’ve been partying, or even people that have been engaged with porn and methamphetamine for several days can get injuries related to overstimulation of the genitals and wounds that can be quite distressing for people. In the emergency department see people that may have only ever used methamphetamine once and they have a reaction like a stroke or a seizure from a high dose.”

Why Current Approaches Fail: The Treatment-Focused Limitation

Healthcare System Responses Prove Inadequate

Analysis of low-barrier substance use disorder programmes reveals why treatment-focused approaches cannot solve drug-related STI prevention challenges. Among 393 patients initiating care, 84.7% completed screening tests, revealing substantial infection burdens: current or past hepatitis C in 38.4%, HIV in 2.3%, and chronic hepatitis B in 0.5%.

Despite identifying 61 new active infections—including HIV, syphilis, gonorrhoea, chlamydia, and hepatitis cases—treatment linkage remained problematic. Only 33.3% of hepatitis C cases achieved care connection, whilst 37.8% of patients remained non-immune to hepatitis B and 43.9% to hepatitis A.

Professor Jason Ong, director of Australia’s largest public sexual health clinic, explains the fundamental problem: “hardly anyone was using condoms and this had led to increased rates of STIs. It is for a variety of reasons, predominantly driven by things like people are no longer in fear of getting HIV. They also think an STI is curable so they don’t mind getting it. So they drop the condoms.”

Infrastructure Cannot Compensate for Behavioural Risk

Even comprehensive healthcare infrastructure proves insufficient when substance use compromises decision-making. Professor Ong notes: “in Victoria, the Melbourne Sexual Health Centre is the only sexual health clinic for the whole of Victoria, so we are meant to be serving around five million people which is almost impossible. Whereas NSW has about 30 sexual health clinics.”

Kirby Institute epidemiologist Skye McGregor identifies additional barriers: “people dropped off getting tested during Covid and they haven’t seen it rebound. It’s hard to get an appointment quickly with the GP, it’s very hard to get an appointment at sexual health clinics that have free or very-low cost testing.”

Yet even when healthcare access improves, fundamental behavioural risks persist. Longitudinal research following 447 men who have sex with men through 1,854 visits found cumulative STI incidence reached 55%. Despite some behavioural modifications after STI diagnosis—methamphetamine use declining from 50% to 35% and median sexual partners reducing from 5 to 2—STI and HIV incidence remained high.

Evidence-Based Interventions Show Limited Effectiveness

Systematic review of eHealth interventions analysing 14 randomised trials demonstrates the limitations of current approaches. The analysis shows very low to low certainty evidence for effectiveness, with short-term STI reduction showing minimal impact (d=0.17, 95% CI -0.18 to 0.52).

Research examining criminal justice-involved populations—where intervention opportunities are maximised—reveals similar limitations. Systematic review of 58 studies found that education-focused interventions typically employed didactic rather than skill-building approaches, showing greater success in increasing knowledge and intentions than in reducing actual risk behaviours.

High-Risk Populations: Concentrated Vulnerabilities

Criminal Justice-Involved Populations

Criminal justice settings reveal concentrated vulnerabilities requiring targeted drug-related STI prevention approaches. Systematic review found that 62.1% of participants across research programmes were Black, highlighting racial disparities in both incarceration and health outcomes.

Despite intervention opportunities, only 3 studies (5.2%) focused on sexual or gender minorities, with just 1 targeting Black men who have sex with men—a population experiencing disproportionately high rates of both HIV and incarceration. This research gap represents what investigators term “a disparity in how HIV is addressed.”

People Who Inject Drugs: Multiple Transmission Pathways

Research examining people who inject drugs (PWID) reveals that sexual transmission contributes substantially to bloodborne infection spread, accounting for at least 10% of new HIV cases according to epidemiological modelling. PWID face increased STI risk varying by gender, setting, substance type, and presence of mental disorders.

Despite substantial evidence that behavioural interventions can improve sexual health among PWID, implementation studies remain scarce. This research-practice gap reflects fundamental challenges in translating evidence into effective prevention programmes.

The Medical Reality: STI Categories and Consequences

Understanding the medical consequences reveals why drug-related STI prevention requires urgent attention. Bacterial infections prove particularly problematic because substance use undermines the protective behaviours necessary for prevention.

Bacterial STIs: Preventable Yet Increasing

Syphilis, caused by bacteria and curable if detected early, affects approximately half of infected individuals without symptoms, requiring screening for diagnosis. Australian STI management guidelines note that whilst high prevalence remains among specific populations, syphilis is increasing in major cities nationally.

Chlamydia represents the most reported communicable disease in Australia, typically spreading through unprotected sex. Most infected individuals show no symptoms whilst potentially transmitting to partners. Without treatment, chlamydia causes serious complications including infertility and chronic pain, with previous infection providing no immunity against reinfection.

Gonorrhoea, caused by bacteria infecting multiple body sites, is most commonly diagnosed in men who have sex with men and young people in remote areas lacking sexual health clinic access. Recent research from Monash University suggests bacterial vaginosis should also be classified as sexually transmitted, affecting one in three women and causing complications including infertility and premature labour.

Viral STIs: Lifelong Consequences

Viral STIs—including hepatitis B, herpes simplex virus, HIV and human papillomavirus—create lifelong health management challenges. For herpes and HIV, antiviral medications can modulate disease progression but cannot cure infection, whilst hepatitis B antivirals help control the virus and slow liver damage.

The Ultimate Tragedy: Preventable Infant Deaths

Congenital syphilis cases demonstrate the most devastating consequences of failed drug-related STI prevention. Dr Belinda Hengel from the Kirby Institute found that 25% of babies born with congenital syphilis were stillborn, with untreated infections causing approximately half of all cases to end in miscarriage, stillbirth, neonatal death or permanent disability.

In 2024, six cases were reported, down from 20 the previous year. Yet as Dr Hengel states: “even one case of congenital syphilis is too many” and represents “a failure in our health care system.”

Beyond Health: Substance Use Creates Broader Risks

Criminal justice observations reveal that substance-related sexual health risks extend beyond infection transmission. Mr Justice Haddon-Cave noted in one case: “Your deteriorating mental health had much to do with your history of drug use and in particular your cannabis habit. This is another example of the danger of cannabis use and its ability to induce psychotic behaviour in young men.”

Judge Lord Nimmo Smith observed: “I do not subscribe to the notion that this is a harmless recreational drug. In your case, I think that it may well have contributed to your being unable to make the distinction between fantasy and reality which is essential for normal moral judgements.”

Road Safety Assistant Commissioner Stephen Leane reports the expanding impact: “You’re more likely to have drugs in your system than alcohol now, sadly, if you’re involved as a driver in a fatal collision.”

The Prevention Imperative: Evidence-Based Economic Arguments

Research demonstrates that prevention-focused approaches offer superior economic returns compared to treatment-based strategies. Analysis indicates that “for every amount we spend today on evidence-based drug prevention programmes, we can save up to 30 times as much in future health and social care cost.”

Screening programmes within criminal justice settings consistently demonstrate cost-effectiveness, yet current approaches focus predominantly on identifying existing infections rather than preventing the substance use that drives transmission.

Current treatment-focused strategies generate enormous ongoing costs whilst addressing consequences rather than causes. Patients initiating substance use disorder care demonstrate substantial unmet infection-related needs, requiring expensive lifelong management for preventable diseases.

The evidence reveals a clear conclusion: effective STI prevention requires addressing substance use as a primary causal factor. Current approaches that attempt to manage consequences whilst ignoring causes will continue failing, generating enormous costs whilst protecting neither individuals nor communities.

Researchers examining criminal justice interventions conclude that high-risk populations urgently need more empirical and modelling studies. They point out that current research gaps “represent a disparity in how HIV is addressed.”

Studies examining people who inject drugs conclude that “integration of sexual health into prevention programs for PWID is essential to curb transmission of STI, including HIV, among PWID and their sexual partners.”

The statistical evidence demonstrates that individuals under the influence of psychoactive substances cannot reliably make rational decisions regarding sexual health protection. This fundamental reality makes comprehensive drug-related STI prevention strategies essential for protecting public health and reducing healthcare costs.

Prevention-focused policies addressing substance use offer genuine prospects for reversing current trends, yet implementation requires acknowledgement that treatment-alone approaches cannot solve problems rooted in voluntary drug consumption decisions.